PMEF
TNGX icon

Point72 Middle East FZE’s Tango Therapeutics TNGX Stock Holding History

Point72 Middle East FZE’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-34,353
Closed -$340K – 1205
2023
Q4 		$340K Buy
+34,353
New +$298K 0.01% 923
2023
Q2 		– Sell
-3,583
Closed -$14.2K – 2057
2023
Q1 		$14.2K Buy
+3,583
New +$20.8K ﹤0.01% 1460

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Point72 Middle East FZE's TNGX Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Tango Therapeutics (TNGX) in Q1 2024, closing a stake of 34,353 shares — an estimated $340K sold.

Point72 Middle East FZE first reported a position in TNGX in Q1 2023 and held it in 2 quarters. The position peaked at $340K in Q4 2023. 126 funds tracked by Wall St. Rank hold TNGX as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Tango Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 34,353 Tango Therapeutics shares in Q1 2024, an estimated $340K.
  • Point72 Middle East FZE first reported a position in Tango Therapeutics in Q1 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Tango Therapeutics position peaked at $340K in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.